Click below to read more about the great benefits:

- The unique advantages of protein delivery with SAINT-PhD.

- Summary of the key benefits of protein transfection by SAINT-PhD.

- Delivery of IgG-FITC using SAINT-PhD: comparison of the standard and the alternative protocol.

- How SAINT-PhD outperforms the competition.

 
Recent SAINT-PhD article:
Pajak B, Apoptosis. 2008 Apr;13(4):509-22. Bisindolylmaleimide IX facilitates extrinsic and
initiates intrinsic apoptosis in TNF-alpha-resistant human colon adenocarcinoma COLO 205 cells.
(Recombinant biologically functional Bcl-2 protein (R&D Systems Inc., Minneapolis, MN, USA) was
delivered into COLO 205 cells with SAINT-PhD [1-methyl-4-(cis-9-dioleyl)methylpyridinium-chloride
(SAINT-18) 1,2-Dioleyl-sn-glycero-3-phosphoethanolamine (DOPE)] reagent according to the
producer’s instruction (Synvolux Therapeutics, Groningen, The Netherlands).)

1. Van der Gun BT, J Control Release. 2007 Nov 20;123(3):228-38. Epub 2007 Aug 23, Serum
insensitive, intranuclear protein delivery by the multipurpose cationic lipid SAINT-2.
(Profection using Saint-2. “SAINT-2:DOPE (SD; 0.75 mM) and SAINT-2 (S; 0.75 mM) were purchased
from Synvolux Therapeutics Inc.(Groningen, The Netherlands).”)

SAINT-PhD product description and protocols:

SAINT-PhD consists of a proprietary cationic pyridinium amphiphile and a helper lipid.
Upon mixture of SAINT-PhD with the protein a particle of approximately 200nm in diameter is formed. In this particle the protein is enwrapped by at least one bilayer of lipids. Furthermore, in the complex formed only non-covalent interactions are present between SAINT-PhD and the protein. The cationic amphiphiles on the surface of the particle have high affinity for the negatively charged cell surface. Upon fusion or entrapment of the particle the protein is released into the cytoplasm of the cell. The proteins delivered by SAINT-PhD are functional and unmodified.